

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 55801-003US1	Application No. 10/584,109
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Kenichiro Kosai et al		
		Filing Date 6/22/2006	Group Art Unit 1633	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes No
	AL						
	AM						
	AN						
	AO						
	AP						

Other Documents (include Author, Title, Date, and Place of Publication)							
Examiner Initial	Desig. ID	Document					
/QN/	AQ	Shah, Bukhtiar H. and Catt, Kevin J., "A central role of EFG receptor transactivation in angiotensin II-induced cardiac hypertrophy", Trends in Pharmacological Sciences, Vol. 24, No. 5, pp 239-244, abstract, 2003.					
/QN/	AR	Hiroaki Ushikoshi et al., CD9 gene therapy inhibits cardiac hypertrophy and tachycardia, and attenuates the remodeling after myocardial infarction in mice", Molecular Therapy, Vol. 11, Supplement 1, pp 359-360 , 2005.					
	AS						

98421.doc

Examiner Signature	/Quang Nguyen/	Date Considered	02/24/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			